Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: PRECEDEX

Summary for Tradename: PRECEDEX

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: PRECEDEX

Clinical Trials for: PRECEDEX

Dexmedetomidine Sedation With Third Molar Surgery
Status: Terminated Condition: Anesthesia

Dexmedetomidine Pharmacokinetics in the Obese
Status: Completed Condition: Obesity

Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Status: Recruiting Condition: Unstable Angina; Coronary Artery Bypass Graft; Dexmedetomidine; Lidocaine; Myocardial Injury; Arrhythmia; Blood Electrolyte Balance

The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children
Status: Completed Condition: Hemodynamic Instability

Comparison of Propofol to Precedex With Propofol for Emergence and Recovery in Patients Having Craniotomy Surgery
Status: Completed Condition: Cranitomy Surgery

Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
Status: Recruiting Condition: Strabismus; Delirium on Emergence; Pediatric Disorders

Dexmedetomidine vs Fentanyl for BMT
Status: Completed Condition: Otitis

Dexmedetomidine in Spinal Anesthesia
Status: Recruiting Condition: Blood Pressure; Anxiety

Comparison of Dexmedetomidine and Remifentanil Infusion During CABG
Status: Completed Condition: Coronary Artery Bypass Graft; Hypokalemia; Cardiac Arrhythmia; Dexmedetomidine; Remifentanil

Dexmedetomidine in Pediatric Tonsillectomy
Status: Completed Condition: Pediatric Adenotonsillectomy; Post Operative Analgesia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038Dec 17, 1999RXYes<disabled><disabled>
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038Dec 17, 1999RXYes<disabled><disabled>
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038Dec 17, 1999RXYes4,910,214*PED<disabled>Y<disabled>
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038Dec 17, 1999RXYes6,716,867*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PRECEDEX

Drugname Dosage Strength RLD Submissiondate
dexmedetomidineInjection100 mcg/mLPrecedex4/8/2009
dexmedetomidineInjection4 mcg/mL, 50 mL and 100 mL vialsPrecedex12/26/2013

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology